Medication guidelines for glucagon-like peptide-1 receptor agonist （2023 edition）
- VernacularTitle:胰高血糖素样肽1受体激动剂类药物用药指导（2023版）
- Author:
Haijiao SI
1
,
2
;
Limei ZHAO
3
;
Shuang CAI
4
;
Keke WANG
4
;
Jiaxin WANG
1
;
Fei GAO
1
;
Huixia LIU
1
;
Ming SUN
2
;
Yu WANG
1
;
Tong LIU
5
Author Information
1. Dept. of Pharmacy，Air Force Hospital in North War Zone of PLA，Shenyang 110042，China
2. College of Life Sciences and Biopharmaceuticals，Shenyang Pharmaceutical University，Shenyang 110016，China
3. Dept. of Pharmacy，Shengjing Hospital of China Medical University，Shenyang 110004，China
4. Dept. of Pharmacy，the First Affiliated Hospital of China Medical University，Shenyang 110122，China
5. Liaoning Provincial Pharmaceutical Society，Shenyang 110167，China
- Publication Type:Journal Article
- Keywords:
type 2 diabetes mellitus;
glucagon-like
- From:
China Pharmacy
2023;34(11):1281-1292
- CountryChina
- Language:Chinese
-
Abstract:
The prevalence of diabetes in China is increasing year by year， and has become a health issue of close concern to the whole society. Glucagon-like peptide-1 （GLP-1） receptor agonist （GLP-1RA）， as a new class of glucose-lowering drugs， is now widely used in the treatment of type 2 diabetes mellitus （T2DM） because of its significant glucose-lowering efficacy and low risk of hypoglycemia. As the level of evidence for its effects on improving cardiovascular system and renal protection and reducing body mass continues to improve， its status in the treatment guidelines for T2DM is gradually increasing. Currently， nine GLP-1RA drugs have been approved for the clinical treatment of T2DM in China. Although all of these drugs exert hypoglycemic effects based on the activation of GLP-1 receptors in the body， the differences in their own structures and natural GLP-1 amino acid homology lead to large differences in pharmacokinetic parameters and clinical efficacy among different analogs. In order to enable clinicians and pharmacists to have a full understanding of the characteristics and clinical evidence of these analogs and to better perform their therapeutic effects， Liaoning Provincial Pharmaceutical Society organized clinical medicine and pharmacy experts to develop a medication guide for nine GLP-1RA drugs to provide a reference for clinical medication needs and promote rational and standardized use by compiling and summarizing the pharmacological characteristics， clinical applications， adverse reactions， interactions， the medications in special populations and medication management.
